Literature DB >> 12514008

Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.

James J Schmidt1, Robert G Stafford.   

Abstract

The seven botulinum neurotoxins (BoNTs) are zinc metalloproteases that cleave neuronal proteins involved in neurotransmitter release and are among the most toxic natural products known. High-throughput BoNT assays are needed for use in antibotulinum drug discovery and to characterize BoNT protease activities. Compared to other proteases, BoNTs exhibit unusually stringent substrate requirements with respect to amino acid sequences and polypeptide lengths. Nonetheless, we have devised a strategy for development of fluorigenic BoNT protease assays, based on earlier structure-function studies, that has proven successful for three of the seven serotypes: A, B, and F. In synthetic peptide substrates, the P(1) and P(3)' residues were substituted with 2,4-dinitrophenyl-lysine and S-(N-[4-methyl-7-dimethylamino-coumarin-3-yl]-carboxamidomethyl)-cysteine, respectively. By monitoring the BoNT-catalyzed increase in fluorescence over time, initial hydrolysis rates could be obtained in 1 to 2 min when BoNT concentrations were 60 ng/ml (about 1 nM) or higher. Each BoNT cleaved its fluorigenic substrate at the same location as in the neuronal target protein, and kinetic constants indicated that the substrates were selective and efficient. The fluorigenic assay for BoNT B was used to characterize a new competitive inhibitor of BoNT B protease activity with a K(i) value of 4 micro M. In addition to real-time activity measurements, toxin concentration determinations, and kinetic studies, the BoNT substrates described herein may be directly incorporated into automated high-throughput assay systems to screen large numbers of compounds for potential antibotulinum drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514008      PMCID: PMC152407          DOI: 10.1128/AEM.69.1.297-303.2003

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  21 in total

1.  High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.

Authors:  L Li; B R Singh
Journal:  Protein Expr Purif       Date:  1999-12       Impact factor: 1.650

2.  High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F.

Authors:  J J Schmidt; R G Stafford; C B Millard
Journal:  Anal Biochem       Date:  2001-09-01       Impact factor: 3.365

3.  Enzymatic autocatalysis of botulinum A neurotoxin light chain.

Authors:  S A Ahmed; M P Byrne; M Jensen; H B Hines; E Brueggemann; L A Smith
Journal:  J Protein Chem       Date:  2001-04

4.  High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity.

Authors:  C Anne; F Cornille; C Lenoir; B P Roques
Journal:  Anal Biochem       Date:  2001-04-15       Impact factor: 3.365

5.  A novel mechanism for Clostridium botulinum neurotoxin inhibition.

Authors:  Subramaniam Eswaramoorthy; Desigan Kumaran; Subramanyam Swaminathan
Journal:  Biochemistry       Date:  2002-08-06       Impact factor: 3.162

6.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

Review 7.  How botulinum and tetanus neurotoxins block neurotransmitter release.

Authors:  Y Humeau; F Doussau; N J Grant; B Poulain
Journal:  Biochimie       Date:  2000-05       Impact factor: 4.079

8.  Botulinum toxin A for axillary hyperhidrosis (excessive sweating).

Authors:  M Heckmann; A O Ceballos-Baumann; G Plewig
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

Review 9.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

Review 10.  Tetanus and botulinum neurotoxins: turning bad guys into good by research.

Authors:  O Rossetto; M Seveso; P Caccin; G Schiavo; C Montecucco
Journal:  Toxicon       Date:  2001-01       Impact factor: 3.033

View more
  45 in total

1.  The role of exoproteases in governing intraneuronal metabolism of botulinum toxin.

Authors:  Lance L Simpson; Andrew B Maksymowych; Hirokazu Kouguchi; Garrett Dubois; Roop S Bora; Suresh Joshi
Journal:  Protein J       Date:  2005-04       Impact factor: 2.371

2.  A fluorescence detection platform using spatial electroluminescent excitation for measuring botulinum neurotoxin A activity.

Authors:  Kim E Sapsford; Steven Sun; Jesse Francis; Shashi Sharma; Yordan Kostov; Avraham Rasooly
Journal:  Biosens Bioelectron       Date:  2008-06-18       Impact factor: 10.618

3.  Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification.

Authors:  Dongxia Wang; Jakub Baudys; Yiming Ye; Jon C Rees; John R Barr; James L Pirkle; Suzanne R Kalb
Journal:  Anal Biochem       Date:  2012-09-24       Impact factor: 3.365

4.  Substrates and controls for the quantitative detection of active botulinum neurotoxin in protease-containing samples.

Authors:  Karine Bagramyan; Bruce E Kaplan; Luisa W Cheng; Jasmin Strotmeier; Andreas Rummel; Markus Kalkum
Journal:  Anal Chem       Date:  2013-05-22       Impact factor: 6.986

5.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

6.  A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.

Authors:  Dejan Caglič; Kristin M Bompiani; Michelle C Krutein; Petr Čapek; Tobin J Dickerson
Journal:  J Vis Exp       Date:  2013-12-27       Impact factor: 1.355

7.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

Review 8.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

9.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

10.  Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.

Authors:  Yuan-Ping Pang; Anuradha Vummenthala; Rajesh K Mishra; Jewn Giew Park; Shaohua Wang; Jon Davis; Charles B Millard; James J Schmidt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.